Quarterly report pursuant to Section 13 or 15(d)

STOCK-BASED COMPENSATION

v3.23.2
STOCK-BASED COMPENSATION
 6 Months Ended
Jun. 30, 2023
Share-Based Payment Arrangement [Abstract]  
STOCK-BASED COMPENSATION

NOTE 10 – STOCK-BASED COMPENSATION

 

The Company previously granted stock options under its 2005 Equity Incentive Plan (the “2005 Incentive Plan”), under which no further grants can be made. In addition, prior to May 17, 2023, the Company had previously granted stock options and stock awards under the Abeona Therapeutics Inc. 2015 Equity Incentive Plan (the “2015 Incentive Plan”). As of May 17, 2023, no further grants can be made under the 2015 Incentive Plan. The Company now grants stock options and stock awards under the Abeona Therapeutics Inc. 2023 Equity Incentive Plan (the “2023 Incentive Plan”) which was approved by stockholders on May 17, 2023. As of June 30, 2023, there were 149,291 shares available to be granted under the 2023 Incentive Plan. In addition, in 2023, the Company’s board of directors approved various restricted stock awards to be granted to six new hires as inducement grants (“Inducement Grants”).

 

The following table summarizes stock-based compensation expense for the three and six months ended June 30, 2023 and 2022 (in thousands):

 

    2023     2022     2023     2022  
   

For the three months ended June 30,

    

For the six months ended June 30,

  
    2023     2022     2023     2022  
                                 
Research and development   $ 218     $ 184     $ 404     $ 556  
General and administrative     709       540       1,293       1,030  
Total stock-based compensation expense   $ 927     $ 724     $ 1,697     $ 1,586  

 

 

Stock Options

 

The Company estimates the fair value of each option award on the date of grant using the Black-Scholes option valuation model. The Company then recognize the grant date fair value of each option as compensation expense ratably using the straight-line attribution method over the service period (generally the vesting period). The Black-Scholes model incorporates the following assumptions:

 

  ● Expected volatility – the Company estimates the volatility of the share price at the date of grant using a “look-back” period which coincides with the expected term, defined below. The Company believes using a “look-back” period which coincides with the expected term is the most appropriate measure for determining expected volatility.
     
  ● Expected term – the Company estimates the expected term using the “simplified” method, as outlined in SEC Staff Accounting Bulletin No. 107, “Share-Based Payment.”
     
  ● Risk-free interest rate – the Company estimates the risk-free interest rate using the U.S. Treasury yield curve for periods equal to the expected term of the options in effect at the time of grant.
     
  ● Dividends – the Company uses an expected dividend yield of zero because the Company has not declared nor paid a cash dividend, nor are there any plans to declare a dividend.

 

The Company estimated the fair value of stock options granted in the periods presented utilizing a Black-Scholes option-valuation model utilizing the following assumptions:

 

    For the six months ended June 30,  
    2023*     2022  
             
Expected volatility     n/a       95.1% - 96.0%  
Expected term     n/a       6.07 - 6.08 years  
Risk-free interest rate     n/a       1.7% - 3.3%  
Expected dividend yield     n/a       0%

 

* the Company did not grant any stock options in the six months ended June 30, 2023.

 

The following table summarizes stock option activity for the 2015 Incentive Plan and the 2005 Incentive Plan during the six months ended June 30, 2023 (there were no stock options granted under the 2023 Incentive Plan during the six months ended June 30, 2023):

 

                Weighted Average        
          Weighted     Remaining     Aggregate  
    Number of     Average     Contractual Term     Intrinsic Value  
    Options     Exercise Price     (years)     (in thousands)  
                         
Outstanding at December 31, 2022     240,770     $ 37.04       6.42     $ —  
Granted     —     $ —       —     $ —  
Cancelled/forfeited     (10,047 )   $ 36.19       —     $ —  
Exercised     —     $ —       —     $ —  
Outstanding at June 30, 2023     230,723     $ 37.08       5.82     $ —  
Exercisable     169,637     $ 36.33       5.09     $ —  
Unvested     61,086     $ 39.17       7.87     $ —  

 

The aggregate intrinsic value of options is calculated as the difference between the exercise price of the underlying options and the fair value of the Company’s common stock for those options that had exercise prices lower than the fair value of the Company’s common stock. As of June 30, 2023, the total compensation cost related to non-vested option awards not yet recognized was approximately $2.0 million with a weighted average remaining vesting period of 1.7 years.

 

 

Restricted Stock

 

The following table summarizes restricted stock award activity for the 2023 Incentive Plan, 2015 Incentive Plan and Inducement Grants during the six months ended June 30, 2023:

 

          Weighted Average  
          Grant Date Fair  
    Number of Awards     Value Per Unit  
             
Outstanding at December 31, 2022     816,958     $ 5.35  
Granted     1,817,559     $ 3.96  
Cancelled/forfeited     (46,394 )   $ 4.40  
Vested     (21,820 )   $ 28.34  
Outstanding at June 30, 2023     2,566,303     $ 4.18  

 

As of June 30, 2023, there was approximately $9.7 million of total unrecognized compensation expense related to unvested restricted stock awards, which is expected to be recognized over a weighted average vesting period of 2.5 years. The total fair value of restricted stock awards that vested during the six months ended June 30, 2023 was $0.6 million.